Sutro Biopharma Inc

More Details of Sutro Biopharma Inc Company

Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.

Company Info

Company codeSTRO

Company nameSutro Biopharma Inc

IPO dateSep 27, 2018

Founded at2003

CEOMs. Jane Chung

Number of employees310

Security typeOrdinary Share

Fiscal year-endSep 27

Address111 Oyster Point Blvd.

CitySOUTH SAN FRANCISCO

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code94080

Phone16503928412

Websitehttps://www.sutrobio.com/

Company codeSTRO

IPO dateSep 27, 2018

Founded at2003

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Jane Chung

President, Chief Executive Officer, Director

98.31K

+39.76%

Dr. Venkatesh Srinivasan, Ph.D.

Chief Technical Operations Officer

52.08K

+35.51%

Mr. Daniel Hunter Petree

Independent Director

22.46K

+454.77%

Dr. Anne Borgman, M.D.

Chief Medical Officer

--

Dr. Jon Marc Wigginton, M.D.

Independent Director

--

Dr. Michael (Mike) Dybbs, Ph.D.

Independent Director

--

Ms. Connie L. Matsui

Independent Chairman of the Board

--

Ms. Sukhi Jagpal

Director

--

Mr. Joseph M. Lobacki

Independent Director

--

Mr. James P. (Jim) Panek

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Ms. Jane Chung

President, Chief Executive Officer, Director

98.31K

+39.76%

Dr. Venkatesh Srinivasan, Ph.D.

Chief Technical Operations Officer

52.08K

+35.51%

Mr. Daniel Hunter Petree

Independent Director

22.46K

+454.77%

Dr. Anne Borgman, M.D.

Chief Medical Officer

--

Dr. Jon Marc Wigginton, M.D.

Independent Director

--

Dr. Michael (Mike) Dybbs, Ph.D.

Independent Director

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholder

Update time: Sun, Apr 6

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

Suvretta Capital Management, LLC

8.91%

BlackRock Institutional Trust Company, N.A.

7.51%

RA Capital Management, LP

5.29%

The Vanguard Group, Inc.

5.02%

Kynam Capital Management LP

4.35%

Other

68.92%

Shareholder Statistics

Shareholder

Proportion

Suvretta Capital Management, LLC

8.91%

BlackRock Institutional Trust Company, N.A.

7.51%

RA Capital Management, LP

5.29%

The Vanguard Group, Inc.

5.02%

Kynam Capital Management LP

4.35%

Other

68.92%

Type

Shareholder

Proportion

Hedge Fund

33.76%

Investment Advisor/Hedge Fund

24.76%

Investment Advisor

14.75%

Corporation

3.25%

Research Firm

3.03%

Venture Capital

2.86%

Individual Investor

1.15%

Pension Fund

0.46%

Bank and Trust

0.12%

Other

15.86%

Institutional Shareholding

Update time: Tue, Mar 4

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

282

70.21M

83.81%

-8.43M

2024Q4

299

65.68M

79.84%

-13.78M

2024Q3

295

64.44M

78.61%

-17.80M

2024Q2

286

64.98M

79.66%

-15.82M

2024Q1

291

55.64M

88.75%

-15.66M

2023Q4

302

58.38M

95.62%

-12.57M

2023Q3

306

61.36M

101.61%

-9.98M

2023Q2

312

60.26M

100.55%

-11.07M

2023Q1

320

58.55M

98.20%

-11.55M

2022Q4

332

54.70M

96.18%

-13.75M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Suvretta Capital Management, LLC

7.46M

8.91%

+275.00K

+3.83%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

6.29M

7.51%

+542.02K

+9.43%

Dec 31, 2024

RA Capital Management, LP

4.43M

5.29%

+4.43M

--

Mar 28, 2025

The Vanguard Group, Inc.

4.21M

5.02%

+13.43K

+0.32%

Dec 31, 2024

Kynam Capital Management LP

3.64M

4.35%

+1.57M

+76.22%

Dec 31, 2024

Merck & Co Inc

2.72M

3.25%

+2.72M

--

Dec 31, 2024

Vestal Point Capital, LP

2.57M

3.07%

+2.57M

--

Dec 31, 2024

Citadel Advisors LLC

2.46M

2.93%

+332.00K

+15.61%

Dec 31, 2024

Point72 Asset Management, L.P.

2.20M

2.62%

-799.91K

-26.69%

Dec 31, 2024

Samsara BioCapital, LLC

2.20M

2.62%

--

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

Range Cancer Immunotherapy ETF

0.76%

Invesco NASDAQ Future Gen 200 ETF

0.31%

ALPS Medical Breakthroughs ETF

0.11%

Avantis US Small Cap Equity ETF

0.01%

ProShares Ultra Nasdaq Biotechnology

0.01%

iShares Micro-Cap ETF

0.01%

Invesco Nasdaq Biotechnology ETF

0.01%

Fidelity Enhanced Small Cap ETF

0.01%

Global X Russell 2000 ETF

0%

iShares Russell 2000 ETF

0%

Range Cancer Immunotherapy ETF

Proportion0.76%

Invesco NASDAQ Future Gen 200 ETF

Proportion0.31%

ALPS Medical Breakthroughs ETF

Proportion0.11%

Avantis US Small Cap Equity ETF

Proportion0.01%

ProShares Ultra Nasdaq Biotechnology

Proportion0.01%

iShares Micro-Cap ETF

Proportion0.01%

Invesco Nasdaq Biotechnology ETF

Proportion0.01%

Fidelity Enhanced Small Cap ETF

Proportion0.01%

Global X Russell 2000 ETF

Proportion0%

iShares Russell 2000 ETF

Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

0.900USD

Sutro Biopharma Inc

0.900

Overview

Company